文献速递炎症性肠病

口服姜黄素预防克罗恩病术后复发不优于安慰剂:随机对照试验

Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-08-27

法国8家转诊中心的双盲随机对照试验纳入62例接受肠切除术的克罗恩病患者,均服用硫唑嘌呤(2.5 mg/kg),随机分为口服姜黄素3 g/天组(n=31)或安慰剂组(n=31)治疗6个月。第6个月时,姜黄素组术后复发(Rutgeerts评分≥i2)18例(58%),安慰剂组21例(68%)(P=.60);姜黄素组严重复发(Rutgeerts评分≥i3)比例55%显著高于安慰剂组26%(P=.034)。研究因中期分析无效而终止。

要点

  • 姜黄素3 g/天联合硫唑嘌呤6个月,术后复发率与安慰剂无显著差异(58% vs 68%,P=.60)。
  • 姜黄素组严重复发(Rutgeerts≥i3)比例55%显著高于安慰剂组26%(P=.034)。
  • 两组生活质量评分(P=.80)和严重不良事件(16% vs 6%,P=.42)无显著差异。

核心结论

  • 在接受手术并服用硫嘌呤类药物的克罗恩病患者中,姜黄素预防术后复发不优于安慰剂。
  • 两组生活质量和严重不良事件无显著差异,研究因中期分析无效而终止。

研究设计与样本

  • 患者均服用硫唑嘌呤2.5 mg/kg,随机分为口服姜黄素3 g/天组(n=31)或相同安慰剂组(n=31),治疗6个月后行结肠镜检查。
  • 主要终点为第6个月术后复发(Rutgeerts评分≥i2,中心判读),计划在入组50%时进行意向治疗中期分析。

主要发现

  • 第6个月术后复发(Rutgeerts评分≥i2):姜黄素组18例(58%)vs 安慰剂组21例(68%)(P=.60)。
  • 严重复发(Rutgeerts评分≥i3):姜黄素组55% vs 安慰剂组26%(P=.034)。
  • 第6个月临床复发(CD活动指数评分>150):安慰剂组45% vs 姜黄素组30%(P=.80)。
  • 第6个月生活质量评分两组无显著差异(P=.80)。
  • 严重不良事件:安慰剂组6% vs 姜黄素组16%(P=.42)。

关键数值与推荐

  • 术后复发定义:Rutgeerts评分≥i2(中心判读)。
  • 严重复发定义:Rutgeerts评分≥i3。
  • 临床复发定义:CD活动指数评分>150。

临床怎么用

  • 对于接受肠切除术并服用硫唑嘌呤2.5 mg/kg的克罗恩病患者,口服姜黄素3 g/天6个月未显示优于安慰剂预防术后复发。
  • 姜黄素组严重复发(Rutgeerts≥i3)比例显著高于安慰剂组,需关注。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Recurrence of Crohn's disease (CD) after surgery is a major concern. Curcumin has anti-inflammatory properties and induces endoscopic remission in patients with ulcerative colitis. We investigated the efficacy of curcumin vs placebo in preventing post-operative recurrence of CD, based on endoscopic and clinical indices, in patients receiving concomitant thiopurine therapy. METHODS: We conducted a double-blind randomized controlled trial at 8 referral centers in France, from October 2014 through January 2018, of 62 consecutive patients with CD undergoing bowel resection. Patients received azathioprine (2.5 mg/kg) and were randomly assigned to groups given oral curcumin (3 g/day; n = 31) or an identical placebo (n = 31) for 6 months, and were then evaluated by colonoscopy. We also collected data on CD activity index, results from laboratory tests, and answers to quality of life questionnaires during this 6-month period. The primary endpoint was postoperative recurrence of CD in each group (Rutgeerts' index score ≥i2) at month 6 (determined by central reading). An interim analysis (intent to treat) was scheduled after 50% of the patients were enrolled. RESULTS: At month 6, postoperative recurrence (Rutgeerts' index score ≥i2) occurred in 18 patients (58%) receiving curcumin and 21 patients (68%) receiving placebo (P = .60). A significantly higher proportion of patients receiving curcumin (55%) had a severe recurrence of CD (Rutgeerts' index score ≥i3) than patients receiving placebo (26%) (P = .034). We observed a clinical recurrence of CD (CD activity index score >150) at month 6 in 45% of patients receiving placebo and 30% of patients receiving curcumin (P = .80). Quality of life scores at month 6 did not differ significantly between groups (P = .80). Severe adverse events developed in 6% of patients receiving placebo and 16% of patients receiving curcumin (P = .42). CONCLUSIONS: In a randomized controlled trial of patients who underwent surgery for CD and received thiopurine treatment, we found that curcumin was no more effective than placebo in preventing CD recurrence. There were no significant differences between groups in quality of life or severe adverse events. The study was discontinued after interim analysis due to futility. ClinicalTrials.gov no: NCT 02255370.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Bommelaer G, Laharie D, Nancey S, et al. Oral Curcumin No More Effective Than Placebo in Preventing Recurrence of Crohn's Disease After Surgery in a Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2019. PMID: 31470175. doi:10.1016/j.cgh.2019.08.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。